JP2006524660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524660A5 JP2006524660A5 JP2006505327A JP2006505327A JP2006524660A5 JP 2006524660 A5 JP2006524660 A5 JP 2006524660A5 JP 2006505327 A JP2006505327 A JP 2006505327A JP 2006505327 A JP2006505327 A JP 2006505327A JP 2006524660 A5 JP2006524660 A5 JP 2006524660A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- substituted
- chloro
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- -1 benzo [1, 3] dioxol-5-yl Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0309944 | 2003-04-30 | ||
| GB0329500A GB0329500D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
| GB0329505A GB0329505D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
| PCT/EP2004/004569 WO2004096752A1 (en) | 2003-04-30 | 2004-04-29 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006524660A JP2006524660A (ja) | 2006-11-02 |
| JP2006524660A5 true JP2006524660A5 (enExample) | 2010-09-16 |
| JP4603531B2 JP4603531B2 (ja) | 2010-12-22 |
Family
ID=33424535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505327A Expired - Fee Related JP4603531B2 (ja) | 2003-04-30 | 2004-04-29 | スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7625950B2 (enExample) |
| EP (1) | EP1622860B1 (enExample) |
| JP (1) | JP4603531B2 (enExample) |
| CN (1) | CN1777575B (enExample) |
| AT (1) | ATE547395T1 (enExample) |
| AU (1) | AU2004234066B2 (enExample) |
| BR (1) | BRPI0410025A (enExample) |
| CA (1) | CA2523582A1 (enExample) |
| ES (1) | ES2383298T3 (enExample) |
| MX (1) | MXPA05011596A (enExample) |
| WO (1) | WO2004096752A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003259296A1 (en) | 2002-07-30 | 2004-02-16 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
| GB0313612D0 (en) * | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
| US7528120B2 (en) | 2003-08-28 | 2009-05-05 | Novartis Ag | Aminopropanol derivatives |
| WO2005041899A2 (en) | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
| GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| US8039674B2 (en) | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
| PL1772145T3 (pl) | 2004-07-16 | 2011-08-31 | Kyorin Seiyaku Kk | Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym |
| BRPI0514316A (pt) | 2004-08-13 | 2008-06-10 | Praecis Pharm Inc | métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p) |
| RU2376285C2 (ru) | 2004-10-12 | 2009-12-20 | Киорин Фармасьютикал Ко., Лтд. | Процесс получения гидрохлорида 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенилэтил]-1,3-пропандиола] и его гидратов, а также промежуточные продукты их получения |
| BRPI0607435A2 (pt) | 2005-02-14 | 2010-04-06 | Univ Virginia | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, e, uso de um composto |
| GB0513431D0 (en) | 2005-06-30 | 2005-08-10 | Kherion Technology Ltd | Prophylactic compositions and uses |
| DK1932522T3 (da) * | 2005-10-07 | 2012-07-02 | Kyorin Seiyaku Kk | Terapeutisk middel mod leversygdom indeholdende 2-amino-1,3-propandiolderivat som aktiv bestanddel |
| CN101346346B (zh) | 2005-12-15 | 2012-08-22 | 田边三菱制药株式会社 | 胺化合物及其医药用途 |
| JP2009528274A (ja) | 2006-01-27 | 2009-08-06 | ユニバーシティ オブ バージニア パテント ファンデーション | 神経因性疼痛の治療法 |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| EP1987013A1 (en) | 2006-02-09 | 2008-11-05 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
| WO2007112322A2 (en) | 2006-03-28 | 2007-10-04 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
| CN101501049B (zh) | 2006-08-08 | 2013-04-24 | 杏林制药株式会社 | 氨基磷酸酯衍生物以及将它们作为有效成分的s1p受体调节剂 |
| RU2458044C2 (ru) * | 2006-08-08 | 2012-08-10 | Киорин Фармасьютикал Ко., Лтд. | Производное аминоспирта и иммунодепрессивное средство, содержащее его в качестве активного ингредиента |
| WO2008064337A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| EP2097397A1 (en) | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
| EP2099741A2 (en) | 2006-11-21 | 2009-09-16 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| BRPI0813683A2 (pt) * | 2007-06-14 | 2019-09-24 | Mitsubishi Tanabe Pharma Corp | composto amina e uso farmacêutico do mesmo |
| CA2700539A1 (en) | 2007-09-24 | 2009-04-02 | Allergan, Inc. | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity |
| TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| BRPI0915052A2 (pt) | 2008-05-08 | 2019-09-24 | Allergan Inc | compostos de 1,7-difenil-1,2,3,5,6,7-hexa-hidropirido [3,2,1-ij] quinolina substituído terapeuticamente úteis |
| US8143291B2 (en) | 2008-05-09 | 2012-03-27 | Allergan, Inc. | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| EP2342205B1 (en) | 2008-08-27 | 2016-04-20 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| WO2011050054A2 (en) * | 2009-10-23 | 2011-04-28 | Allergan, Inc. | Coumarin compounds as receptor modulators with therapeutic utility |
| CA2780859A1 (en) * | 2009-12-10 | 2011-06-16 | Novartis Ag | Fty720 halogenated derivatives |
| EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
| ES2558087T3 (es) | 2010-03-03 | 2016-02-01 | Arena Pharmaceuticals, Inc. | Procesos para la preparación de moduladores del receptor S1P1 y formas cristalinas de los mismos |
| CN102260178A (zh) * | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69524962D1 (de) * | 1994-08-22 | 2002-02-14 | Welfide Corp | Benzolderivate und deren medizinische verwendung |
| GB2309868A (en) * | 1996-01-30 | 1997-08-06 | Sony Corp | Radio receiver detects FCCH synchronising signal |
| IL155065A (en) | 1997-04-04 | 2004-01-04 | Mitsubishi Pharma Corp | History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them |
| ATE298741T1 (de) | 1997-04-10 | 2005-07-15 | Pharmacia & Upjohn Co Llc | Polyaromatische verbindungen zur behandlung von herpes-infektionen |
| ATE314383T1 (de) * | 2001-03-26 | 2006-01-15 | Novartis Pharma Gmbh | 2-amino-propanol derivate |
| JP2002316985A (ja) * | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| PT1431284E (pt) * | 2001-09-27 | 2008-01-21 | Kyorin Seiyaku Kk | Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor |
| US6963012B2 (en) * | 2001-09-27 | 2005-11-08 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivative, addition salt thereof, and immunosuppressant |
| AU2003273865A1 (en) * | 2002-09-13 | 2004-04-30 | Novartis Ag | Amino-propanol derivatives |
-
2004
- 2004-04-29 WO PCT/EP2004/004569 patent/WO2004096752A1/en not_active Ceased
- 2004-04-29 BR BRPI0410025-5A patent/BRPI0410025A/pt not_active IP Right Cessation
- 2004-04-29 US US10/554,556 patent/US7625950B2/en not_active Expired - Fee Related
- 2004-04-29 EP EP04730206A patent/EP1622860B1/en not_active Expired - Lifetime
- 2004-04-29 CN CN2004800110595A patent/CN1777575B/zh not_active Expired - Fee Related
- 2004-04-29 AT AT04730206T patent/ATE547395T1/de active
- 2004-04-29 MX MXPA05011596A patent/MXPA05011596A/es active IP Right Grant
- 2004-04-29 AU AU2004234066A patent/AU2004234066B2/en not_active Ceased
- 2004-04-29 ES ES04730206T patent/ES2383298T3/es not_active Expired - Lifetime
- 2004-04-29 CA CA002523582A patent/CA2523582A1/en not_active Abandoned
- 2004-04-29 JP JP2006505327A patent/JP4603531B2/ja not_active Expired - Fee Related